{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:22:49Z","timestamp":1793395369193,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIA\/NIH","award":["U01 AG016976"],"award-info":[{"award-number":["U01 AG016976"]}]},{"name":"NIA\/NIH","award":["U01 AG016976"],"award-info":[{"award-number":["U01 AG016976"]}]},{"name":"NIA\/NIH","award":["U01 AG016976"],"award-info":[{"award-number":["U01 AG016976"]}]},{"name":"NIA\/NIH","award":["U01 AG016976"],"award-info":[{"award-number":["U01 AG016976"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer\u2019s disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the \"Alzheimer's Disease Research Centers\" were analysed; the mean follow-up period was 7.9\u00a0years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs\u2009+] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6\u00a0years of follow up in AChEIs\u2009+\u2009and then declined, while in AChEIs\u2212 it progressively declined so that at the end of follow-up (13.6\u00a0years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs\u2009+\u2009(\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). This trend was driven by LOAD (\u0394-MMSE:\u221210.8 vs. \u22125.7 points;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), although a similar effect was observed in VD (\u0394-MMSE:\u221211.6 vs. \u22128.8;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53\u20130.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-16476-w","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T13:02:44Z","timestamp":1657976564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia"],"prefix":"10.1038","volume":"12","author":[{"given":"Marco","family":"Zuin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cherubini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Volpato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Zuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,16]]},"reference":[{"key":"16476_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s41999-019-00265-2","volume":"11","author":"C Mattiuzzi","year":"2020","unstructured":"Mattiuzzi, C. & Lippi, G. Worldwide disease epidemiology in the older persons. Eur. Geriatr. Med. 11, 147\u2013153. https:\/\/doi.org\/10.1007\/s41999-019-00265-2 (2020).","journal-title":"Eur. Geriatr. Med."},{"key":"16476_CR2","first-page":"15891599","volume":"322","author":"Z Arvanitakis","year":"2019","unstructured":"Arvanitakis, Z., Shah, R. C. & Bennett, D. A. Diagnosit and management of dementia: Review. JAMA 322, 15891599 (2019).","journal-title":"JAMA"},{"key":"16476_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/gps.1402","volume":"21","author":"A Takeda","year":"2006","unstructured":"Takeda, A. et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer\u2019s disease. Int. J. Geriatr. Psychiatry. 21, 17\u201328. https:\/\/doi.org\/10.1002\/gps.1402 (2006).","journal-title":"Int. J. Geriatr. Psychiatry."},{"key":"16476_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108352","author":"G Marucci","year":"2020","unstructured":"Marucci, G. et al. Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108352 (2020).","journal-title":"Neuropharmacology"},{"key":"16476_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00002512-200421070-00004","volume":"21","author":"DG Wilkinson","year":"2004","unstructured":"Wilkinson, D. G., Francis, P. T., Schwam, E. & Payne-Parrish, J. Cholinesterase inhibitors used in the treatment of Alzheimer\u2019s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 21, 453\u2013478. https:\/\/doi.org\/10.2165\/00002512-200421070-00004 (2004).","journal-title":"Drugs Aging."},{"key":"16476_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593","author":"J Birks","year":"2006","unstructured":"Birks, J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD005593 (2006).","journal-title":"Cochrane Database Syst. Rev."},{"key":"16476_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000486546","volume":"45","author":"R Knight","year":"2018","unstructured":"Knight, R., Khondoker, M., Magill, N., Stewart, R. & Landau, S. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement. Geriatr. Cogn. Disord. 45, 131\u2013151. https:\/\/doi.org\/10.1159\/000486546 (2018).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"16476_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13195-018-0457-9","volume":"10","author":"KX Dou","year":"2018","unstructured":"Dou, K. X. et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer\u2019s disease: A network meta-analysis of 41 randomized controlled trials. Alzheimers Res. Ther. 10, 126. https:\/\/doi.org\/10.1186\/s13195-018-0457-9 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"16476_CR9","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","volume":"359","author":"T Erkinjuntti","year":"2002","unstructured":"Erkinjuntti, T. et al. Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: A randomised trial. Lancet 359, 1283\u20131290. https:\/\/doi.org\/10.1016\/S0140-6736(02)08267-3 (2002).","journal-title":"Lancet"},{"key":"16476_CR10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"H Kavirajan","year":"2007","unstructured":"Kavirajan, H. & Schneider, L. S. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials. Lancet Neurol. 6, 782\u2013792. https:\/\/doi.org\/10.1016\/S1474-4422(07)70195-3 (2007).","journal-title":"Lancet Neurol."},{"key":"16476_CR11","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3892\/mmr.2019.10374","volume":"20","author":"K Sharma","year":"2019","unstructured":"Sharma, K. Cholinesterase inhibitors as Alzheimer\u2019s therapeutics (Review). Mol. Med. Rep. 20, 1479\u20131487. https:\/\/doi.org\/10.3892\/mmr.2019.10374 (2019).","journal-title":"Mol. Med. Rep."},{"key":"16476_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","volume":"16","author":"T Kennedy-Martin","year":"2015","unstructured":"Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S. & Johnston, J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 16, 495. https:\/\/doi.org\/10.1186\/s13063-015-1023-4 (2015).","journal-title":"Trials"},{"key":"16476_CR13","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1111\/j.1532-5415.2010.03032.x","volume":"58","author":"A Cherubini","year":"2010","unstructured":"Cherubini, A., Del Signore, S., Ouslander, J., Semla, T. & Michel, J. P. Fighting against age discrimination in clinical trials. J. Am. Geriatr. Soc. 58, 1791\u20131796 (2010).","journal-title":"J. Am. Geriatr. Soc."},{"key":"16476_CR14","doi-asserted-by":"crossref","unstructured":"Peres-Zepeda MU, Cherubini A., Garcia Pena C, Zengarini E., Gutierrez Robledo LM. Clinical trials on aging research. In Aging research- methodological issues. Garcia Pena C, Gutierrez Robledo LM, Peres-Zepeda MU, (Springer) 115\u2013127 (2018).","DOI":"10.1007\/978-3-319-95387-8_9"},{"key":"16476_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JAD-2009-0926","volume":"16","author":"PT Nelson","year":"2009","unstructured":"Nelson, P. T. et al. Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer\u2019s disease and AD + DLB. J. Alzheimers Dis. 16, 29\u201334. https:\/\/doi.org\/10.3233\/JAD-2009-0926 (2009).","journal-title":"J. Alzheimers Dis."},{"key":"16476_CR16","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.archger.2008.07.006","volume":"49","author":"M Calabria","year":"2009","unstructured":"Calabria, M., Geroldi, C., Lussignoli, G., Sabbatini, F. & Zanetti, O. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer\u2019s disease: A 21-month follow-up \u2018\u201creal world\u201d\u2019 study. Arch. Gerontol. Geriatr. 49, e6\u2013e11. https:\/\/doi.org\/10.1016\/j.archger.2008.07.006 (2009).","journal-title":"Arch. Gerontol. Geriatr."},{"key":"16476_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/11310960-000000000-00000","volume":"24","author":"A Santoro","year":"2010","unstructured":"Santoro, A. et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer\u2019s disease: A prospective, observational study. CNS Drugs 24, 163\u2013176. https:\/\/doi.org\/10.2165\/11310960-000000000-00000 (2010).","journal-title":"CNS Drugs"},{"key":"16476_CR18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2020.136","author":"N Vaci","year":"2020","unstructured":"Vaci, N. et al. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: Retrospective health record study. Br. J. Psychiatry https:\/\/doi.org\/10.1192\/bjp.2020.136 (2020).","journal-title":"Br. J. Psychiatry"},{"key":"16476_CR19","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"DP Gill","year":"2013","unstructured":"Gill, D. P. et al. Differences in rate of functional decline across three dementia types. Alzheimer\u2019s Dementia. 9, S63\u2013S71 (2013).","journal-title":"Alzheimer\u2019s Dementia."},{"key":"16476_CR20","first-page":"278","volume":"2","author":"MH Pilon","year":"2016","unstructured":"Pilon, M. H. et al. Differences in rate of cognitive decline and caregiver burden between alzheimer\u2019s disease and vascular dementia: A retrospective study. Neurology (ECronicon). 2, 278\u2013286 (2016).","journal-title":"Neurology (ECronicon)."},{"key":"16476_CR21","unstructured":"Kumar A, Sharma S. Donepezil. [Updated 2020 Aug 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513257\/"},{"key":"16476_CR22","unstructured":"National Institute for Health and Care Excellence (UK). Dementia: Assessment, management and support for people living with dementia and their carers. London: National Institute for Health and Care Excellence (UK); 2018 Jun. (NICE Guideline, No. 97.) 11, Cholinesterase inhibitors and memantine for dementia. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK536484\/"},{"key":"16476_CR23","doi-asserted-by":"crossref","unstructured":"Rolinski, M., Fox, C., Maidment, I. & McShane, R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease. Cochrane Database Syst. Rev.\u00a0(3), CD006504 (2012).","DOI":"10.1002\/14651858.CD006504.pub2"},{"key":"16476_CR24","doi-asserted-by":"publisher","first-page":"pyv086","DOI":"10.1093\/ijnp\/pyv086","volume":"19","author":"S Matsunaga","year":"2016","unstructured":"Matsunaga, S., Kishi, T., Yasue, I. & Iwata, N. Cholinesterase inhibitors for lewy body disorders: A meta-analysis. Int. J. Neuropsychopharmacol. 19, pyv086 (2016).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"16476_CR25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011832","author":"Xu Hong","year":"2021","unstructured":"Hong, Xu. et al. Long term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000011832 (2021).","journal-title":"Neurology"},{"key":"16476_CR26","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/(SICI)1097-0258(20000615\/30)19:11\/12<1607::AID-SIM449>3.0.CO;2-O","volume":"19","author":"MS Mendiondo","year":"2000","unstructured":"Mendiondo, M. S., Wesson Ashford, J., Kryscio, R. J. & Schmitt, F. A. Modelling mini mental state examination changes in alzheimer\u2019s disease. Statist. Med. 19, 1607\u20131616 (2000).","journal-title":"Statist. Med."},{"issue":"1","key":"16476_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JAD-2009-0926","volume":"16","author":"PT Nelson","year":"2009","unstructured":"Nelson, P. T. et al. Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with alzheimer\u2019s disease and AD + DLB. J Alzheimers Dis. 16(1), 29\u201334. https:\/\/doi.org\/10.3233\/JAD-2009-0926 (2009).","journal-title":"J Alzheimers Dis."},{"key":"16476_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/alzrt85","volume":"3","author":"C Wattmo","year":"2011","unstructured":"Wattmo, C., Wallin, \u00c5. K., Londos, E. & Minthon, L. Predictors of long-term cognitive outcome in Alzheimer\u2019s disease. Alzheimer\u2019s Res. Ther. 3, 23 (2011).","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"4","key":"16476_CR29","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3233\/JAD-181047","volume":"69","author":"S Karen","year":"2019","unstructured":"Karen, S., Tim, W., Karoline, K., Oliver, S. & Zuzana, S. T. W. Rate of cognitive decline in alzheimer\u2019s disease stratified by age. J. Alzheimers Dis. 69(4), 1153\u20131160 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"16476_CR30","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/eht182","volume":"34","author":"P Nordstr\u00f6m","year":"2013","unstructured":"Nordstr\u00f6m, P., Religa, D., Wimo, A., Winblad, B. & Eriksdotter, M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer\u2019s disease. Eur. Heart J. 34, 2585\u20132591. https:\/\/doi.org\/10.1093\/eurheartj\/eht182 (2013).","journal-title":"Eur. Heart J."},{"key":"16476_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/ageing\/afx098","volume":"47","author":"C Mueller","year":"2018","unstructured":"Mueller, C., Perera, G., Hayes, R. D., Shetty, H. & Stewart, R. Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer\u2019s disease: A retrospective survival analysis. Age Ageing. 47, 88\u201394. https:\/\/doi.org\/10.1093\/ageing\/afx098 (2018).","journal-title":"Age Ageing."},{"issue":"1","key":"16476_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jagp.2019.06.008","volume":"28","author":"ECK Tan","year":"2020","unstructured":"Tan, E. C. K. et al. Do Acetylcholinesterase inhibitors prevent or delay psychotropic prescribing in people with dementia? Analyses of the Swedish dementia registry. Am. J. Geriatric Psychiatry 28(1), 108\u2013117 (2020).","journal-title":"Am. J. Geriatric Psychiatry"},{"key":"16476_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.trci.2016.12.005","volume":"3","author":"M Ba","year":"2017","unstructured":"Ba, M. et al. Alzheimer\u2019s disease neuroimaging initiative. The prevalence and biomarkers\u2019 characteristic of rapidly progressive Alzheimer\u2019s disease from the Alzheimer\u2019s Disease Neuroimaging Initiative database. Alzheimers Dement. (N Y) 3, 107\u2013113. https:\/\/doi.org\/10.1016\/j.trci.2016.12.005 (2017).","journal-title":"Alzheimers Dement. (N Y)"},{"key":"16476_CR34","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/archneurol.2011.189","volume":"68","author":"C Schmidt","year":"2011","unstructured":"Schmidt, C. et al. Rapidly progressive Alzheimer disease. Arch. Neurol. 68, 1124\u20131130. https:\/\/doi.org\/10.1001\/archneurol.2011.189 (2011).","journal-title":"Arch. Neurol."},{"key":"16476_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann, G. et al. Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34, 939\u2013944. https:\/\/doi.org\/10.1212\/wnl.34.7.939 (1984).","journal-title":"Neurology"},{"key":"16476_CR36","doi-asserted-by":"publisher","unstructured":"McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. J Alzheimers Dis. 9, 417-423 (2006); https:\/\/doi.org\/10.3233\/jad-2006-9s347.","DOI":"10.3233\/jad-2006-9s347"},{"key":"16476_CR37","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/wnl.43.2.250","volume":"43","author":"GC Rom\u00e1n","year":"1993","unstructured":"Rom\u00e1n, G. C. et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250\u2013260. https:\/\/doi.org\/10.1212\/wnl.43.2.250 (1993).","journal-title":"Neurology"},{"key":"16476_CR38","doi-asserted-by":"publisher","unstructured":"Pezzotti P, Scalmana S, Mastromattei A, Di Lallo D; Progetto Alzheimer Working Group. The accuracy of the MMSE in detecting cognitive impairment when administered by general practitioners: a prospective observational study. BMC Fam. Pract. 9, 29 (2008); https:\/\/doi.org\/10.1186\/1471-2296-9-29.","DOI":"10.1186\/1471-2296-9-29"},{"key":"16476_CR39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 46, 399\u2013424 (2011).","journal-title":"Multivar. Behav. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16476-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16476-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16476-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:21:15Z","timestamp":1669332075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16476-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16476"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16476-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,16]]},"assertion":[{"value":"22 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AC reports personal fees from Nestle, personal fees from Bristol Myers Squibb and payment \/honoraria from MSD, outside the submitted work; SV reports Consulting fees from Angelini SPA and Payment\/honoraria from Abbot Vifor, outside from the submitted work. MZ, GZ and LF have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12214"}}